Level Bio ABFRA:4MB +8.00%23 Altman Z-Score is 2.69 as of Jul. 09, 2026, which is 52% below its 10-year median of 5.60. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Level Bio AB ranks better than 53.92% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.7 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
Level Bio AB has a Altman Z-Score of 2.69, indicating it is in Grey Zones. This implies that Level Bio AB is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Level Bio AB's Altman Z-Score or its related term are showing as below:
FRA:4MB'
s Altman Z-Score Range Over the Past 10 Years
Min: -0.42 Med: 5.6 Max: 20.18
Current: 2.7
During the past 13 years, Level Bio AB's highest Altman Z-Score was 20.18. The lowest was -0.42. And the median was 5.60.
Level Bio AB (FRA:4MB) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Level Bio AB Altman Z-Score Related Terms
Level Bio AB Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Level Bio AB's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4MB vs TMO, DHR, IDXX: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, Level Bio AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Bio AB Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Level Bio AB's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Level Bio AB's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.0107
+
1.4
*
0
+
3.3
*
-0.2028
+
0.6
*
1.3634
+
1.0
*
2.5255
=
2.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Level Bio AB (FRA:4MB) has a Altman Z-Score of 2.69 as of Jul. 09, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Level Bio AB and its competitors. This is 52% below median its historical median of 5.60. According to the industry distribution chart, Level Bio AB ranks #94 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 46.1%.
Is Level Bio AB's Altman Z-Score too high?
Level Bio AB's current Altman Z-Score of 2.69 is 52% below median its 10-year median of 5.60. The Medical Diagnostics & Research industry median Altman Z-Score is 2.39. Level Bio AB's value of 2.69 is 12.6% above this industry median. Based on the distribution chart, Level Bio AB ranks #94 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's Altman Z-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #94 out of 204 companies for Altman Z-Score. This puts Level Bio AB in the upper half of its industry. The industry median Altman Z-Score is 2.39. Level Bio AB's value of 2.69 is 12.6% above this benchmark. While the company's 10-year median is 5.60 vs. the industry median of 2.39, Level Bio AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.39, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Bio AB's current Altman Z-Score of 2.69 is 12.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Level Bio AB and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Bio AB's current Altman Z-Score is 2.69, which is 52% below median its own 10-year median of 5.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current Altman Z-Score of 2.69. The current Altman Z-Score is 2.69, which is 52% below median its 10-year median of 5.60 and 12.6% above the Medical Diagnostics & Research industry median of 2.39. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current Altman Z-Score is 2.69 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score
Get the complete analysis for FRA:4MB
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4MB has been successfully added to your 
